Danaher Corporation (DHR)

Market Cap	161.05B
Revenue (ttm)	24.27B
Net Income (ttm)	3.50B
Shares Out	706.35M
EPS (ttm)	4.87
PE Ratio	46.85
Forward PE	28.13
Dividend	$1.28 (0.56%)
Ex-Dividend Date	Dec 26, 2025

Volume	2,576,056
Open	225.13
Previous Close	224.84
Day's Range	224.12 - 228.66
52-Week Range	171.00 - 258.23
Beta	0.92
Analysts	Strong Buy
Price Target	248.47 (+8.97%)
Earnings Date	Jan 28, 2026

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for man...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1969
• Employees: 63,000
• Stock Exchange: NYSE
• Ticker Symbol: DHR
• Website: https://www.danaher.com

Financial Performance

In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.

Analyst Summary

According to 18 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $248.47, which is an increase of 8.97% from the latest price.

Price Target

$248.47

(8.97% upside)

Analyst Consensus: Strong Buy